@KenOliveLab

Asc Prof. of Medicine, Columbia University, views own. Pancreatic cancer, translational therapeutics, metabolism, systems, paracrine interactions. It all fits.

 New York, NY, USA
cancer.columbia.edu/profile/kenneth-p-olive-phd
Joined August 2018
  • Tweets2.5K
  • Following370
  • Followers3.7K
265Media
OK, this one is really meaningful for our whole team. Our preclinical paper on pan-RAS inhibition in pancreatic cancer is now online @Nature. Led by OliveLab student @ulawasko and Revolution Medicines colleagues JingJing Jiang and Mallika Singh. nature.com/articles/s41586-0…

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

Nature - RMC-7977, a multi-selective RAS(ON) inhibitor, exhibits potent tumour-selective activity in multiple pre-clinical models of pancreatic ductal adenocarcinoma through a combination of...

nature.com
19
55
9
219
30,101
Sad to miss the first #PCAMChat24. Briefly, this is Ken Olive from @columbiacancer. I lead a translational research lab dedicated to #PDAC research. Excited to join in for part 2!
10
706
Suddenly seeing a huge number of fellow scientists show up on BlueSky. FYI I'm one of them. Come follow me: @kenolivelab.bsky.social
2
5
548
ICYMI, the new issue of @CR_AACR is online and features the print version of the In Focus commentary #PancreaticCancer–Associated Fibroblasts: Where Do We Go from Here? aacrjournals.org/cancerres/a… By Eileen Carpenter, @DebVendramini @MC_Hasselluhn @MaraShermanLab @Pasca_Lab @ednacukierman @KenOliveLab
13
36
5,072
New post on our website with updated information on the clinical development of RAS inhibitors for pancreatic cancer. I'll summarize on twitter sooner, but here's the full version: olivelab.org/ras-inhibitor-2…
1
14
2
43
4,197
KenOliveLab retweeted
Brian Henick@BHenickMD
29 Oct 2024
On behalf of our Phase I program @columbiacancer , proud of @bherzbergmd presenting exciting initial data on IDE397 in MTAP-del tumors at the @EORTC - @theNCI - @AACR conference ir.ideayabio.com/2024-10-25-… We are excited to offer this study to our patients recruit.cumc.columbia.edu/st…

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and...

~33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSCLC patients 9 of 9 responses have confirmed by...

ir.ideayabio.com
1
6
1
49
4,425
Really excited for my postdoc @MC_Hasselluhn who received a 4th percentile score on her K99 application. Folks, she's on the job market!
9
1
1
66
13,038
Revolution Medicines has launched its ph 3 study of RMC-6236 (RASolute 302) in patients with previously treated #PancreaticCancer. 1:1 randomization against physician’s choice of chemotherapy. A registration trial for KRAS inhibitor in pancreatic cancer! clinicaltrials.gov/study/NCT…
4
55
4
149
20,526
KenOliveLab retweeted
Simon Duerr@simonduerr
1 Oct 2024
There is a new tool on BioIcons to turn any protein (in PDB format) into a 2D vector illustration in SVG format. You can upload any PDB file or import from PDB, AlphaFoldDB or ESMFoldDB. Feedback welcome :) bioicons.com/pdb2vector/
19
170
5
773
58,169
We are thrilled to welcome Michel Sadelain, MD, PhD, a global pioneer in CAR-T therapies, to Columbia and the HICCC.
Columbia Medicine
@ColumbiaMed
30 Sep 2024
Columbia welcomes CAR-T pioneer Michel Sadelain, MD, PhD, as the inaugural director of the new Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative at the Herbert Irving Comprehensive Cancer Center. ➡️columbiamed.link/3zCR9iI
Columbia welcomes Michel Sadelain, MD, PhD, Director of the Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative in the Herbert Irving Comprehensive Cancer Center.

ALT Columbia welcomes Michel Sadelain, MD, PhD, Director of the Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative in the Herbert Irving Comprehensive Cancer Center.

3
7
2
58
11,242
KenOliveLab retweeted
Luis Arnes@ARNesLab
17 Sep 2024
I am excited to see this story by my talented Master's Student, Kristina Høj. Her research dives into age-related decline in pancreas regeneration and how it’s linked to a proinflammatory response to injury. @AGA_GHAdvances,@UCPH_BRIC, tinyurl.com/4e2uz2sb
2
2
1
14
1,356
New online perspective article @CR_AACR article timed with the ongoing #PancreaticCancer stroma session at #AACRPan24 Pancreatic Cancer-Associated Fibroblasts: Where do we go from here? A conversation with three experts on the PDAC stroma (@MaraShermanLab @ednacukierman & @Pasca_Lab) led by three fantastic early career faculty (@MC_Hasselluhn @DebVendramini & Eileen Carpenter @UMICHpancreas). Lots of great perspectives on this complex subject! aacrjournals.org/cancerres/a…
14
1
36
6,255
Hiring committees take note...
Alvaro Curiel-García, PhD@AlvaroCurielGa1
2 Sep 2024
That feeling when you submit your first application for a tenure-track faculty! 🧑‍🔬 I am planing to create a "Translational systems oncology" laboratory focused on cell states, hypoxia and targeted therapies where I will use both wet and dry approaches. #faculty #academiclife
11
1,337
KenOliveLab retweeted
CU-DLDRC@cudldrc
3 Sep 2024
Congratulations to CU-DLDRC Associate Director, Timothy Wang, MD, who is the new Vice Chair for Academic Programs for the Department of Medicine at the Vagelos College of Physicians and Surgeons! Dr Wang will add this new role to his portfolio effective September 3rd, 2024.
1
15
906
Replying to @NwosuLab
@NwosuLab @CornellMBG has opened a call for postdoc applicants. Please kindly repost and or forward to potential applicants. Job posting: academicjobsonline.org/ajo/j… Lab website: nwosulab.com
9
12
1,825
KenOliveLab retweeted
Joel Gabre@GabreJoel
22 Aug 2024
Proud to have helped launch the Columbia Early Onset Colorectal Cancer Program @columbiacancer @nyp with @BDionigiMD and Yoanna Pumpalova. cancer.columbia.edu/early-on…

Early Onset Colorectal Cancer Program

The Early Onset Colorectal Cancer Program at Columbia Cancer Center is one of the first of its kind dedicated to young people who have been diagnosed with colorectal cancer.

cancer.columbia.edu
4
1
15
1,881
When everything is urgent, nothing is urgent.
1
10
1,224
The Olive Lab is looking for a postdoc to lead our translational program on RAS inhibition in pancreatic cancer. Should have exceptional scientific and project management skills, and experience with transdisciplinary research. Must be a good human. olivelab.org
2
38
4
84
12,145
They present a preliminary design of a planned Phase 3 trial in 2nd line PDAC patients, randomized to physician's choice.
2
2
1
11
2,889
Data available on their website at: ir.revmed.com/static-files/e…
1
2
9
2,444
Really exciting times for the PDAC field, offering real hope for patients. This is just monotherapy. Can't wait to see combinations!
1
15
2,296
Stunning interim clinical trial data from Revolution Medicines... PFS = 8.1 mo in 2nd line KRAS G12-mutant metastatic #PDAC. OS not yet reached, but already more than a year! Benchmark PFS for this group is 2-3.5 months, behnchmark OS is 6.1-6.9. 1/
8
85
15
246
113,112
All standard caveats apply: single arm data, non randomized, highly scrutinized patients, early phase, selected group, etc. Even with the caveats, the results are exciting IMHO.
1
1
19
2,938
Load more